Хайдер Варрайч - Сердце, которое мы не знаем. История важнейших открытий и будущее лечения сердечно-сосудистых заболеваний
- Название:Сердце, которое мы не знаем. История важнейших открытий и будущее лечения сердечно-сосудистых заболеваний
- Автор:
- Жанр:
- Издательство:Литагент Альпина
- Год:2021
- Город:Москва
- ISBN:9785961473445
- Рейтинг:
- Избранное:Добавить в избранное
-
Отзывы:
-
Ваша оценка:
Хайдер Варрайч - Сердце, которое мы не знаем. История важнейших открытий и будущее лечения сердечно-сосудистых заболеваний краткое содержание
Вы узнаете о строении и функциях сердца и коронарных сосудов, о самых распространенных болезнях, их диагностике, лекарствах, а также о плюсах и минусах популярных методов лечения – катетеризации, кардиостимуляции и электроимпульсной терапии. Книга полна историй из практики автора и его коллег и отсылок к истории медицинской науки.
Хайдер Варрайч объясняет, почему женщины страдают теми же сердечными заболеваниями, что и мужчины, но тип заболевания у них совершенно иной, что общего у коронарных и онкологических заболеваний, как эволюция могла привести нас к настоящей эпидемии ишемической болезни, рассуждает о нынешнем состоянии мировой клинической кардиологии и перспективах ее развития в эпоху внедрения искусственного интеллекта.
Сердце, которое мы не знаем. История важнейших открытий и будущее лечения сердечно-сосудистых заболеваний - читать онлайн бесплатно ознакомительный отрывок
Интервал:
Закладка:
139
Collins R., Reith C., Emberson J, et al. Interpretation of the Evidence for the Efficacy and Safety of Statin Therapy. Lancet. 2016;388:2532–61.
140
Salami JA, Warraich H., Valero-Elizondo J, et al. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013 Insights from the Medical Expenditure Panel Survey. JAMA Cardiology. 2017;2:56–65.
141
Warraich H. J., Salami J. A., Khera R., Valero-Elizondo J, Okunrintemi V, Nasir K. Trends in Use and Expenditures of Brand-Name Atorvastatin After Introduction of Generic Atorvastatin. JAMA Internal Medicine. 2018;178:719–21.
142
Warraich H. The Measles Outbreak Coming Near You. Wall Street Journal. December 3, 2014.
143
Collins, Reith, Emberson, et al. Interpretation of the Evidence.
144
Cohen J. D., Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): An Internet-Based Survey of 10,138 Current and Former Statin Users. Journal of Clinical Lipidology. 2012;6:208–15.
145
Bruckert E, Hayem G, Dejager S., Yau C., Begaud B. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients – The PRIMO Study. Cardiovascular Drugs Therapy. 2005;19:403–14.
146
Finegold J. A., Manisty CH, Goldacre B, Barron AJ, Francis DP. What Proportion of Symptomatic Side Effects in Patients Taking Statins Are Genuinely Caused by the Drug? Systematic Review of Randomized Placebo-Controlled Trials to Aid Individual Patient Choice. European Journal of Preventative Cardiology. 2014;21:464–74.
147
Gupta A., Thompson D., Whitehouse A., et al. Adverse Events Associated with Unblinded, but Bot with Blinded, Statin Therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): A Randomised Double-Blind Placebo-Controlled Trial and Its Non-Randomised Non-Blind Extension Phase. Lancet. 2017;389:2473–81.
148
Price D. D., Finniss D. G., Benedetti F. A Comprehensive Review of the Placebo Effect: Recent Advances and Current Thought. Annual Review of Psychology. 2008;59:565–90.
149
Kaptchuk T. J., Miller F. G. Placebo Effects in Medicine. New England Journal of Medicine. 2015;373:8–9.
150
Simpson S. H., Eurich D. T., Majumdar S. R., et al. A Meta-Analysis of the Association Between Adherence to Drug Therapy and Mortality. British Medical Journal. 2006;333:15.
151
Kam-Hansen S., Jakubowski M., Kelley J. M., et al. Altered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks. Science Translational Medicine. 2014;6:218ra5.
152
Colloca L. Nocebo Effects Can Make You Feel Pain. Science. 2017;358:44.
153
Barron A. J., Zaman N, Cole G. D., Wensel R, Okonko D. O., Francis D. P. Systematic Review of Genuine versus Spurious Side-Effects of Beta-Blockers in Heart Failure Using Placebo Control: Recommendations for Patient Information. International Journal of Cardiology. 2013;168:3572–9.
154
Yusuf S. Why Do People Not Take Life-Saving Medications? The Case of Statins. Lancet. 2016;388:943–5.
155
Serban M. C., Colantonio L. D., Manthripragada A. D., et al. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. Journal of the American College of Cardiology. 2017;69:1386–95.
156
Selva-O’Callaghan A., Alvarado-Cardenas M., Pinal-Fernandez I., et al. Statin-Induced Myalgia and Myositis: An Update on Pathogenesis and Clinical Recommendations. Expert Review of Clinical Immunology. 2018;14:215–24.
157
Levy A. Pill Culture Pops. New York. June 9, 2003.
158
Warraich H. J., Schulman K. A. Health Care Tax Inversions – Robbing Both Peter and Paul. New England Journal of Medicine. 2016;374:1005–7.
159
Warraich, Salami, Khera, Valero-Elizondo, Okunrintemi, Nasir. Trends in Use.
160
Jack J. L. Triumph of the Heart: The Story of Statins. Oxford, UK: Oxford University Press; 2009.
161
Salami J. A., Warraich H. J., Valero-Elizondo J., et al. National Trends in Nonstatin Use and Expenditures Among the U. S. Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. Journal of the American Heart Association. 2018;7.
162
Fredrickson D. S., Altrocchi, P.H., Avioli, L.V, Goodman, D, Goodman, HS. Tangier Disease: Combined Clinical Staff Conference at the National Institutes of Health. Annals of Internal Medicine. 1961:1016–31.
163
Gordon D. J., Probstfield J. L., Garrison R. J., et al. High-Density Lipoprotein Cholesterol and Cardiovascular Disease. Four Prospective American Studies. Circulation. 1989;79:8–15.
164
Forey B. A., Fry J. S., Lee P. N., Thornton A. J., Coombs K. J. The Effect of Quitting Smoking on HDL–Cholesterol – A Review Based on Within-Subject Changes. Biomarker Research. 2013;1:26.
165
Kodama S., Tanaka S., Saito K., et al. Effect of Aerobic Exercise Training on Serum Levels of High-Density Lipoprotein Cholesterol: A Meta-Analysis. Archives of Internal Medicine. 2007;167:999–1008.
166
Berryman C. E., Fleming J. A., Kris-Etherton P. M. Inclusion of Almonds in a Cholesterol-Lowering Diet Improves Plasma HDL Subspecies and Cholesterol Efflux to Serum in Normal-Weight Individuals with Elevated LDL Cholesterol. Journal of Nutrition. 2017;147:1517–23.
167
Investigators A.-H., Boden W. E., Probstfield J.L, et al. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New England Journal of Medicine. 2011;365:2255–67.
168
Group HTC, Landray M. J., Haynes R., et al. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine. 2014;371:203–12.
169
Marz W., Kleber M. E., Scharnagl H., et al. HDL Cholesterol: Reappraisal of Its Clinical Relevance. Clinical Research in Cardiology. 2017;106:663–75.
170
Group HTRC, Bowman L., Hopewell J. C., et al. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. New England Journal of Medicine. 2017;377:1217–27.
171
Voight B. F., Peloso G. M., Orho-Melander M., et al. Plasma HDL Cholesterol and Risk of Myocardial Infarction: A Mendelian Randomisation Study. Lancet. 2012;380:572–80.
172
Khera A. V., Cuchel M., de la Llera-Moya M., et al. Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis. New England Journal of Medicine. 2011;364:127–35.
173
Pew Research Center. Public Trust in Government Remains Near Historic Lows as Partisan Attitudes Shift. May 2017. www.people-press.org/2017/05/03/publictrust-in-government-remains-near-historic-lows-as-partisan-attitudes-shift/.
174
Gallup. Americans’ Trust in Mass Media Sinks to New Low. September 2016. https://news.gallup.com/poll/195542/americans-trust-mass-media-sinks-newlow.aspx.
175
Pew Research Center. Public Confidence in Scientists Has Remained Stable for Decades. April 2017. www.pewresearch.org/fact-tank/2017/04/06/public-confidence-in-scientists-has-remained-stable-for-decades/.
176
Huffington Post. People Who Have Sex Four or More Times a Week Make More Money. August 2013. www.huffingtonpost.com/2013/08/14/more-sex-higherwages_n_3755271.html.
177
Moyer M. W. It’s Not Dementia, It’s Your Heart Medication: Cholesterol Drugs and Memory. Scientific American. September 2010.
178
Yusuf S. Why Do People Not Take Life-Saving Medications? The Case of Statins. Lancet. 2016;388:943–5.
179
Are Statins a Key to Preventing Alzheimer’s Disease? December 2016. www.cnn.com/2016/12/12/health/statins-alzheimers-disease/index.html.
180
Canetto S. S., Sakinofsky I. The Gender Paradox in Suicide. Suicide and Life-Threatening Behavior. 1998;28:1–23.
181
Spurious Correlations. www.tylervigen.com/spurious-correlations.
182
Norton B. J. Karl Pearson and Statistics: The Social Origins of Scientific Innovation. Social Studies of Science. 1978;8:3–34.
183
Kalantar-Zadeh K., Block G., Horwich T., Fonarow G. C. Reverse Epidemiology of Conventional Cardiovascular Risk Factors in Patients with Chronic Heart Failure. Journal of the American College of Cardiology. 2004;43:1439–44.
184
Ravnskov U., Diamond D. M., Hama R., et al. Lack of an Association or an Inverse Association Between Low-Density-Lipoprotein Cholesterol and Mortality in the Elderly: A Systematic Review. British Medical Journal. Open 2016;6: e010401.
185
Collier R. Legumes, Lemons and Streptomycin: A Short History of the Clinical Trial. Canadian Medical Association Journal. 2009;180:23–4.
186
Zetterstrom R. Nobel Prize 1937 to Albert von Szent-Gyorgyi: Identification of Vitamin C as the Anti-Scorbutic Factor. Acta Paediatrica. 2009;98:915–9.
187
Moffet H. H. Sham Acupuncture May Be as Efficacious as True Acupuncture: A Systematic Review of Clinical Trials. Journal of Alternative and Complementary Medicine. 2009;15:213–6.
188
Haygarth J. Of the Imagination as a Cause and as a Cure of Disorders of the Body. Bath, UK: R. Cruttwell; 1800.
189
DiMasi J.A., Grabowski H. G., Hansen R. W. Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. Journal of Health Economics. 2016;47:20–33.
190
Spitz V. Doctors from Hell: The Horrific Account of Nazi Experiments on Humans. Boulder, CO: Sentient Publications; 2005.
191
Berger R. L. Nazi Science – The Dachau Hypothermia Experiments. New England Journal of Medicine. 1990;322:1435–40.
192
Bachrach S. In the Name of Public Health – Nazi Racial Hygiene. New England Journal of Medicine. 2004;351:417–20.
193
Emanuel E. J. The History of Euthanasia Debates in the United States and Britain. Annals of Internal Medicine. 1994;121:793–802.
194
Beecher H. K. Ethics and Clinical Research. New England Journal of Medicine. 1966;274:1354–60.
195
Там же.
196
Там же.
197
Editorial. Sterilization and Its Possible Accomplishments. New England Journal of Medicine. 1934;211:379–80.
198
Brandt A. M. Racism and Research: The Case of the Tuskegee Syphilis Study. Hastings Center Report. 1978;8:21–9.
Читать дальшеИнтервал:
Закладка:
